What is LNSR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.08B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LNSR?

P/E (TTM) is 2.26 and 52-week range is $4.95 to $12.94 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LNSR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LNSR?

The company profile lists revenue (TTM) near $32M, net income (TTM) near $19M, EPS (TTM) near $2.08 when available from the market-data feed. Figures are informational and may lag live markets.

Where is LENSAR Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Orlando, Florida, US, 12.3M shares outstanding, ISIN US52634L1089 when available from company profile and filing metadata.

LENSAR Inc

$LNSR

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$6.37

-1.24%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 150 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The firm has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.

Employees

150

Website

www.lensar.com/

IPO

2020-09-21

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)